Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
Growth and nutritional status:z‐score for height · children and adults with CF
1 finding from 1 review
Intervention not reported
Mortality · children and adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Respiratory outcomes: FEV1 (% predicted): · children and adults with CF
1 finding from 1 review
Intervention not reported
Respiratory outcomes: Antibiotic days per patient in past 3 months · children and adults with CF
1 finding from 1 review
Intervention not reported
Adverse events · children and adults with CF
1 finding from 1 review
Intervention not reported
Annualised relapse rate (ARR) (number of relapses per patient per year) · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Expanded Disability Status Scale (EDSS) score · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
MRI gadolinium‐enhancing T1 lesions · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Serious adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
Intervention not reported
Stroke and other systemic embolic events · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower stroke and other systemic embolic events (high certainty).
1 finding from 1 review
Intervention not reported
All strokes · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower all strokes (high certainty).
1 finding from 1 review
Intervention not reported
Major bleedings · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower major bleedings (moderate certainty).
1 finding from 1 review
Intervention not reported
Intracranial haemorrhages · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower intracranial haemorrhages (high certainty).
1 finding from 1 review